According to @CNBC, JPMorgan highlighted a rare biopharma stock within Wall Street’s top picks for 2026 and said it could more than triple from current levels (source: @CNBC on X, Dec 5, 2025). This implies an upside of over 200% versus the current price, but the post does not disclose the ticker or specific catalysts driving the call (source: @CNBC on X, Dec 5, 2025). The post links to a CNBC article listing 2026 stock selections, and it does not mention any crypto or digital asset market impact (source: @CNBC on X, Dec 5, 2025).